Amsterdam, the Netherlands – 22 February 2019 — Esperite N.V. (Euronext: ESP) and Polski Bank Komórek Macierzystych S.A. (WSE: PBKM) are pleased to announce that they have entered into an Memorandum of Understanding (MoU) regarding the potential acquisition by PBKM of substantially all Cryo-Save’s business related to stem cell banking (the Proposed Acquisition). The Proposed Acquisition leverages the respective strengths and quality standards of the two publicly traded companies that are both leading in the stem cell banking sector. Cryo-Save is one of the largest and longest operating stem cell bank in Europe, in which store more than 330.000 umbilical cord blood samples and tissues. [Read more…]
The Future of Stem Cell Therapy as Treatment for Autism
Treatment for autism is an increasingly important pursuit, as the Center for Disease Control and Prevention (CDC) estimates:
- 1 in 59 children has been identified with autism spectrum disorder (ASD) [Read article]
- Autism occurs in all racial, ethnic, and socioeconomic groups. [Read article]
- Studies in Asia, Europe, and North America have identified ASD to have a prevalence rate of between 1% and 2%. [Data table]
With autism spectrum disorder (ASD) affecting between 1-2% of the population, the condition is becoming of increasing importance and a treatment for autism is becoming a highly sought-after medical breakthrough. [Read more…]
Americord announces five-compartment bags and best-in-industry quality guarantee
New York, NY; February 19, 2019 — Americord Registry announced today that it will begin offering five-compartment freezing bags for all new customers storing cord blood as well as the highest quality guarantee in the industry. While industry-standard freezing bags typically contain two compartments, one holding eighty percent of the cord blood and a second holding twenty percent, Americord’s new freezing bags contain five compartments with twenty percent of the cord blood in each compartment. [Read more…]
StemCyte Receives Phase II IND Clearance for HLA-Matched Cord Blood Mononuclear Stem Cells (MC001)
StemCyte Receives Phase II Investigational New Drug (IND) Clearance from the U.S. Food and Drug Administration (FDA)
BALDWIN PARK, Calif., Jan. 3, 2019 — StemCyte is pleased to announce that the U.S. Food and Drug Administration (FDA), on December 14, 2018, approved its Phase II Investigational New Drug (IND) application for Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood Mononuclear Stem Cells (UCBMNC) (MC001) for the treatment of spinal cord injury. [Read more…]
Cord Blood Banking – Present and Future Outlook
Cord blood banking is defined as the collection and storage of stem cells present within the umbilical cord blood of a newborn for future medical use. Umbilical cord blood is rich in a type of stem cell known as a hematopoietic stem cell (HSC). A large market for the storage of these cells has come into existence over the past 30 years, with public and private cord blood banks now present in all major healthcare markets worldwide. [Read more…]
